|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, tumor growth in mice with SHP2-deficient T-cells was markedly slowed down because of enhanced anti-tumor responses.
|
30972278 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The findings of our study imply that Shp2 is a key factor in the tumor microenvironment to facilitate the TAMs' tumor-suppressing functions in colorectal cancer.
|
31598397 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In each tumor that was sensitive to combined treatment, p(Y542)SHP2 induction was observed in response to ERK signaling inhibition.
|
30605687 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) is ubiquitously expressed in cytoplasmic localization, which in turn confers tumor malignancy and poor prognosis in various human cancers.
|
30685130 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our data indicated that GOF-mutant SHP2 enhanced the abilities of GBM cells for proliferation, migration, and invasion in vitro, and promoted tumor growth in vivo.
|
31807022 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We observed that several oncogenes (eg, MAP2K1, PTPN11, and KRAS) and tumor suppressor genes (eg, EZH2, CDKN2C, and RHOA) strongly exhibit this phenomenon.
|
30785643 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Finding selective inhibitors for Shp2 is useful because although its inhibition is advantageous for the treatment of some types of cancer, inhibition of Shp1 may have the opposite effect, since it acts as a suppressor of tumors.
|
31268558 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Thus, targeting macrophage Shp2 may help to create a Th1-dominant tumor immune microenvironment.
|
29795405 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In the present study, we verified that tumour overexpression of SHP2 and other protein tyrosine phosphatases regulated several cellular processes and contributed to tumorigenesis, which could be introduced to ultrasound molecular imaging for differentiating normal from malignant thyroid diagnostic nodes.
|
29706844 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Mice with Shp-2-deficient T cells also showed no significant improvement in controlling immunogenic tumors and responded similarly to controls to α-PD-1 treatment.
|
29617671 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression.
|
29808009 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The disease has been shown to be associated with loss of function of the tumor suppressor gene "protein tyrosine phosphatase, non-receptor type 11" (PTPN11).
|
29703018 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Using a genetic loss-of-function approach and bone marrow transplantation models for CML and BCR-ABL1<sup>+</sup> B-ALL, we show that SHP2 is required for BCR-ABL1-evoked myeloid and lymphoid neoplasia.
|
28804122 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Altogether these results indicate that SHP-2 is a cartilage tumor suppressor during aging.
|
29085371 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Collectively, the results suggest that upregulation of PTPN11 by B16F0 exosomes to tumor infiltrating lymphocytes would bypass the extracellular control of the immune checkpoints.
|
27930879 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Thus, SHP2 inhibitors have drawn great attention by both inhibiting tumor cell proliferation and activating T cell immune responses toward cancer cells.
|
29155585 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We identify a similar mechanism in tumors with wild-type ptpn11 and dysregulated Gab2, which encodes a Shp2 activator that is overexpressed in human neuroblastomas.
|
28329685 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In addition, we collected and analyzed clinical SCLC specimens and found that Shp2 levels correlated with CA916798 expression in tumor tissues.
|
28423588 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Using paired differentiated and stem cell primary cultures, we investigated the association of SHP2 expression with the tumor stem cell compartment.
|
28852935 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PIAS3, p‑SHP2, SOCS1 and SOCS3 were expressed in higher levels (++ and +++) in 63.6, 90, 87.5 and 81.8% of tumor surrounding brain tissues, which reduced to 13.1, 47.8, 33.3 and 50% in grade I, 11.4, 65.7, 58.3 and 77.1% in grade II, 9.1, 63.6, 38.1 and 31.8% in grade III and 7.1, 66.7, 30.8 and 7.1% in grade IV astrocytomas.
|
28035384 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
A recent study suggested that SHP2 acts as a tumor suppressor during hepatocellular carcinoma (HCC) development.
|
28460481 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, recent studies indicated that Shp2 may act as tumor suppressors in several tumor types.
|
28085101 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, controversies are emerging from many studies, indicating SHP2 has a dual role in different types of tumors.
|
29242509 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Accumulative evidence demonstrates that the protein tyrosine phosphatase Shp2 functions as a powerful tumor promoter in many types of cancers.
|
28208810 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The Cripto-1 (CR-1) derived EGF-CFC family was overexpressed in tumor development enhancing proliferation, epithelial-mesenchymal transition (EMT) and migration of tumor cells.
|
28098905 |
2017 |